KBC Group
APLS

KBC Group’s Apellis Pharmaceuticals APLS Stock Holding History

KBC Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,313
Closed -$93K – 1849
2026
Q1 		$93K Hold
2,313
– – ﹤0.01% 1357
2025
Q4 		$58K Hold
2,313
– – ﹤0.01% 1587
2025
Q3 		$52K Hold
2,313
– – ﹤0.01% 1633
2025
Q2 		$40K Sell
2,313
-1,537
-40% -$28.5K ﹤0.01% 1665
2025
Q1 		$84K Sell
3,850
-100,437
-96% -$2.77M ﹤0.01% 1581
2024
Q4 		$3.33M Buy
104,287
+101,655
+3,862% +$3.06M 0.01% 576
2024
Q3 		$76K Buy
2,632
+679
+35% +$25.1K ﹤0.01% 1467
2024
Q2 		$75K Buy
1,953
+356
+22% +$16.1K ﹤0.01% 1352
2024
Q1 		$94K Sell
1,597
-25
-2% -$1.59K ﹤0.01% 1154
2023
Q4 		$97K Hold
1,622
– – ﹤0.01% 1078
2023
Q3 		$62K Buy
+1,622
New +$71.2K ﹤0.01% 1276

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

KBC Group's APLS Position: Q2 2026 in Review

KBC Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 2,313 shares — an estimated $93K sold.

KBC Group first reported a position in APLS in Q3 2023 and held it in 11 quarters. The position peaked at $3.33M in Q4 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • KBC Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • KBC Group sold 2,313 Apellis Pharmaceuticals shares in Q2 2026, an estimated $93K.
  • KBC Group first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 11 quarters.
  • KBC Group's Apellis Pharmaceuticals position peaked at $3.33M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.